Physician and patient management of type 2 diabetes and factors related to glycemic control in Spain

Nicole Rae Yurgin, Kristina Secnik Boye, Tatiana Dilla, Núria Lara Suriñach, Xavier Badia Llach, Nicole Rae Yurgin, Kristina Secnik Boye, Tatiana Dilla, Núria Lara Suriñach, Xavier Badia Llach

Abstract

The objective of this study was to assess current treatment patterns, blood glucose test strip usage, and treatment compliance in patients with type 2 diabetes mellitus (T2DM) in primary care centers in Spain, and to assess factors related to glycemic control. We conducted a retrospective chart review of patients with T2DM and measured treatment compliance using the Morisky-Green questionnaire. 294 patients were included in the study from a population of patients attending 30 primary care centers throughout Spain. Results showed that the majority of patients were treated with oral monotherapy (36%) and oral combination therapy (35%). Less than half of the patients had good glycemic control (HbA(1c) </= 6.5%). Half of the patients treated pharmacologically reported good compliance with treatment. Logistic regression analyses performed to identify factors associated with glycemic control showed that high body mass index (BMI) and poor compliance were the strongest predictors of poor HbA(1c) control (OR: 2.198 and 1.789, respectively, p < 0.05). In conclusion, in the course of managing diabetes, physicians and patients should attempt to improve compliance and lower BMI, which could lead to better glycemic control.

Keywords: diabetes; glucose control; primary care; treatment adherence; treatment pattern.

Figures

Figure 1
Figure 1
Distribution of current treatment patterns of T2DM patients according to number of years since T2DM diagnosis. Abbreviation: T2DM, type 2 diabetes mellitus.

References

    1. [ADA] American Diabetes Association. Diagnosis and classification of diabetes mellitus. Diabetes Care. 2005;28:S37–S42.
    1. [ADA] American Diabetes Association. Standards of medical care in diabetes. Diabetes Care. 2006;29(Suppl 1):S4–42.
    1. Arroyo J, Badía X, de la Calle H, et al. Tratamiento de los pacien-tes con disbetes mellitus tipo 2 en españa. Medicina Clínica (Barc) 2005;125:166–72.
    1. Bayo J, Latorre PM, García F, et al. Factores de riesgo asociados a la prevalencia de diabetes mellitus no insulinodependiente en Lejona (Vizaya) Medicina Clínica (Barc) 1996;107:572–7.
    1. Benach J, Yasui Y, Borrell C, et al. Material deprivation and leading causes of death by gender: evidence from a nationwide small area study. J Epidemiol Community Health. 2001;55:239–45.
    1. Benito LP, Garcia MR, Puig DM, et al. Pathological characteristics of patients with diabetes mellitus type 2 in Spanish primary care. Revista Clínica Española. 2004;204:18–24.
    1. [BCS] British Cardiac Society, British Hypertension Society, Diabetes UK. JBS2: Joint British Societies’ guidelines on prevention of cardiovascular disease in clinical practice. Heart. 2005;91(Suppl 5):1–52.
    1. Clemente ML, Alonso JA, Córdoba R, et al. Descripción de las guías disponibles en España para el abordaje del tabaquismo en Atención Primaria. Atención Primaria. 1999;24:101–8.
    1. Clua Espuny JL, Puig Junoy J, Ciuranan Roca E, et al. Self-monitoring of blood glucose: evaluation of its prescription and results in type-2 diabetes. Atención Primaria. 1999;24:316–25.
    1. Cramer JA. A systematic review of adherence with medications for diabetes. Diabetes Care. 2004;27:1218–24.
    1. Díaz Grávalos GK, Palmeiro Fernández G, Casado Górriz I, et al. Cumplimiento de los objetivos de control metabólico en diabetes mellitus en el medio rural de Ourense. Revista Española de Salud Pública. 2006;80:67–75.
    1. Farmer A, Wade A, Goyder E, et al. Impact of self monitoring of blood glucose in the management of patients with non-insulin treated diabetes: open parallel group randomised trial. BMJ. 2007;335:132.
    1. Fernández Herraez E, Ferré Larrosa F, Jiménez Alfonso L, et al. Valoración de los factores relacionados con el control de la glucemia en la diabetes mellitus tipo 2. Atención Primaria. 1999;24:39–43.
    1. Franciosi M, Pellegrini F, De Berardis G, et al. Self-monitoring of blood glucose in non-insulin treated diabetic patients: a longitudinal evaluation of its impact on metabolic control. Diabetic Med. 2005;22:900–6.
    1. Gallichan M. Self monitoring of glucose by people with diabetes: evidence based practice. BMJ. 1997;314:964–7.
    1. García Soidán FJ, Novo Rodríguez JM, Vázquez Troitiño F, et al. Diabetes Mellitus tipo 2 [online] [Accessed on March 3, 2007];Guías Clínicas. 2005 5(15) URL: .
    1. González-Clemente JM. Non-insulin dependent diabetes mellitus: care in an area of Barcelona. Medicina Clínica (Barc) 1997;108:91–7.
    1. Grant RW, Buse JB, Meigs JB. Quality of diabetes care in US academic medical centers: low rates of medical regimen change. Diabetes Care. 2005;28:337–442.
    1. Grant RW, Devita NG, Singer DE, et al. Polypharmacy and medication adherence in patients with type 2 diabetes. Diabetes Care. 2003;26:1408–12.
    1. Guerci B, Drouin P, Grange V, et al. Self-monitoring of blood glucose significantly improves metabolic control in patients with type 2 diabetes mellitus: the Auto-Surveillance Intervention Active Study. Diabet Metabol. 2003;29:587–94.
    1. Harris MI. Health care and health status and outcomes for patients with type 2 diabetes. Diabetes Care. 2000;23:754–8.
    1. [IDF] International Diabetes Federation. Global guideline for type 2 diabetes [online] 2005. [Accessed March 3, 2007]. URL: .
    1. [INE] Instituto Nacional de Estadistica [National Institute of Statistics] Demographics and Population. INEbase [online] Madrid: National Institute of Statistics; 2006. [Accessed on December 14, 2006]. Population referring to January 1, 2005 by autonomous communities and sex. URL: .
    1. King H, Aubert RE, Herman WH. Global burden of diabetes 1995–2025: prevalence, numerical estimates, and projections. Diabetes Care. 1998;21:1414–31.

    1. Laing W, Williams R. 1996. Diabetes, a model for health care management, Office of Health Economics, London, 1989 (Paper 92). Cited by: Marks L. Counting the cost: the real impact of non-insulin-dependent diabetes. A King’s Fund report commissioned by the British Diabetic Association.

    1. Martín S, Schneider B, Heinemann L, et al. Self-monitoring of blood glucose in type 2 diabetes and long-term outcome: an epidemiological cohort study. Diabetologia. 2006;49:271–8.
    1. Mata Cases M, Roset Gamisans M, Badia Llach X, et al. Impacto de la disbetes mellitus tipo 2 en la calidad de vida de los pacientes tratados en las consultas de atención primaria en España. Atención Primaria. 2003;31:493–9.
    1. Mino-Leon D, Figueras A, Amato D, et al. Treatment of type 2 diabetes in primary health care: a drug utilization study. Ann Pharmacother. 2005;39:441–5.
    1. Morisky DE, Green LW, Levine DM. Concurrent and predictive validity of a self-reported measure of medication adherence. Med Care. 1986;24:67–74.
    1. Oliva J, Lobo F, Molina B, et al. Direct health care costs of diabetic patients in Spain. Diabetes Care. 2004;27:2616–21.
    1. Olveira G, Soriguer F, Ortega C, et al. Use of reagent materials for self-monitoring in the metropolitan area of Malaga (1994–1996) Atención Primaria. 1998;21:75–80.
    1. Roglic G, Unwin N, Bennett PH, et al. The burden of mortality attributable to diabetes: realistic estimates for the year 2000. Diabetes Care. 2005;28:2130–35.
    1. Sender Palacios MJ, Vernet Vernet M, Larrosa Sáez P, et al. Carac-terísticas sociodemográficas y clínicas de una población de pacientes con diabetes mellitus. Atención Primaria. 2002;29:474–80.
    1. Spann SJ, Nutting PA, Galliher JM, et al. Management of type 2 diabetes in the primary care setting: a practice-based research network study. Ann Fam Med. 2006;4:23–31.
    1. Tamayo-Marco B, Faure-Nogueras E, Roche-Asensio MJ, et al. Prevalence of diabetes and impaired glucose tolerance in Aragon, Spain. Diabetes Care. 1997;20:534–6.
    1. Tremble JM, Donaldson D. Is continued weight gain inevitable in type 2 diabetes mellitus? J Royal Soc Health. 1999;119:235–9.
    1. Turner R, Cull C, Frighi V, et al. Glycemic control with diet, sulfonylurea, metformin, or insulin in patients with type 2 diabetes mellitus: progressive requirement for multiple therapies (UKPDS 49) JAMA. 1999;281:2005–12.
    1. [UKPDS] UK Prospective Diabetes Study Group. Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33) Lancet. 1998;352:837–53.
    1. [WHO] World Health Organization. Prevalence of diabetes in the WHO European region [online] 2007. [Accessed March 3, 2007]. URL: .
    1. World Health Organization Regional Office for Europe. European mortality database. 2007. [Accessed March 3, 2007]. URL:
    1. Zimmet P, Alberti KG, Shaw J. Global and societal implications of the diabetes epidemic. Nature. 2001;414:782–7.
    1. Zorrilla Torras B, Cantero Real JL, Martínez Cortés M. Study of non-insulin-dependent diabetes mellitus in primary care in the community of Madrid using network of sentinel physicians. Atención Primaria. 1997;20:543–8.

Source: PubMed

Sponsorit ja yhteistyökumppanit

Sairaudet

Huumeiden interventiot

3
Tilaa